Treue et al. (2019) reported EGFR-mutated NSCLC with whole exome sequencing data, phosphorylated protein data and computational models, and identified three potential biomarkers for therapy targets. APOBEC, a DNA deaminase, was identified as a gene of mutational heterogeneity which might be associated with tumour migration (Roper et al., 2019). Although a large amount of work have been done on NSCLC and SCLC, the essential differences between NSCLC and SCLC remain to be fully characterized (Sutherland et al., 2011). Here, EGFR is linked to small cell lung carcinoma.